SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Denies Somaxon Pharmaceuticals, Inc. Approval for Insomnia Drug

February 27, 2009 | 
1 min read
Feb 26 (Reuters) - Somaxon Pharmaceuticals Inc said the U.S. health regulators denied approval for its experimental treatment for insomnia in the present form and raised several issues regarding the efficacy data of the drug.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Regulatory
Life-Threatening Liver Toxicity Triggers FDA Freeze on Two Intellia Gene Therapy Studies
October 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
October 29, 2025
 · 
1 min read
 · 
Heather McKenzie
Clarify to employees. Businessman leader is walking with flashlight. vector
FDA
FDA Provides Guidance To Prevent Returned Applications, Aid Patient-Focused Drug Development
October 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Photo of scientists and legal counsel in meeting
Job Trends
8 Companies Hiring Now in Regulatory
October 23, 2025
 · 
2 min read
 · 
Angela Gabriel